AB1157 CLINICAL CHARACTERISTICS OF PATIENTS WITH RHEUMATIC DISEASES AFTER COVID-19 IN THE REPUBLIC OF TATARSTAN
| Autor: | S. Lapshina, N. Shamsutdinova, V. Mukhamadieva, R. Abdrakipov, E. Sukhorukova, A. Sagitova, A. Zakirova, L. Krasnova, D. Abdulganieva |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Annals of the Rheumatic Diseases. 81:1695.2-1695 |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | BackgroundThe management of patients with rheumatic diseases (RD) who have undergone a new coronovirus infection (NCI) is an urgent and significant problem.ObjectivesTo study the course of the NCI and its influence on the course of RD in the Republic of Tatarstan.MethodsFrom June 2020 to January 2022, 159 cases of NCI with a confirmed SarsCoV2 PCR result and/or X-ray computed tomography (CT) of the lungs in patients with RD were analyzed. The study included 104 patients with RA, 36 patients with AS, 18 patients with PsA. RD activity before NCI was low in 56 (35.2%) patients, moderate in 91 (57.3%), and high in 12 (7.5%) patients. Distribution by gender: 113 (71.0%) females, 46 (28.9%) males, mean age 58 [46; 64]. 56 patients (49.5%) were hospitalized, the average age of those hospitalized was 61 [49; 67] year. The average duration of RD at the time of NCI was 11 [7; 16.75] years. The results of clinical and laboratory examinations were evaluated before and 1-3 months after the NCI.ResultsManifestations of infection in patients with RD in terms of frequency and severity were comparable to the course of NCI in the population: intoxication with fever above 38C, respiratory symptoms, ageusia, anosmia, pneumonia. 27.1% (43) of patients had asymptomatic or mild course of COVID-19, 64.1% (102) had moderate course, 8.8% (14) of patients - severe NCI. Lung involvement was detected in 116 (72.9%) patients. Patients received NCI therapy according to national guidelines. The outcome of COVID-19 in 154 (96.9%) patients was recovery, in 5 (3.1%) patients it was fatal, 3 of them were on rituximab therapy. A total of 8 patients received rituximab.After undergoing NCI, 26 (16.4%) patients did not develop an increase in activity, in 76 (47.7%) patients RD corresponded to a moderate degree of activity. In 57 (35.9%) patients RD activity became high, 3 months after the NCI, a significant (pConclusionThe prevalence and course of COVID-19 in patients with RD did not generally differ from those in the population. The most unfavorable course of NCI in terms of life prognosis was observed in patients receiving rituximab for underlying RD. The COVID-19 contributes to an increase in the activity of the main RD.Disclosure of InterestsNone declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|